Remote Mood Monitoring in diabetes
Research type
Research Study
Full title
A pilot study to determine the ability of an established telehealth mood monitoring system to evaluate the impact on mood of initiating an injectable therapy in individuals with type 2 diabetes
IRAS ID
113334
Contact name
Rury Holman
Contact email
Sponsor organisation
Research and Development Department
Research summary
A pilot study to determine the ability of an established telehealth mood monitoring system to evaluate the impact on mood of initiating an injectable therapy in individuals with type 2 diabetes
Type 2 diabetes occurs when blood sugar levels in the body become too high. It is usually treated by following a healthy diet and by taking tablets. However, as time goes by diet and tablets alone are no longer able to control adequately blood sugar levels. At this stage people with diabetes need to take injections of insulin or in some cases injections of another recently available hormone called GLP-1.
We know that for many people having to take injections every day for the rest of their lives comes as quite a shock and can lead to them feeling depressed. Healthcare professionals may ask about symptoms of depression at diabetes check-ups but often there is a six-month gap between appointments. A system has been developed for people with mental health problems to allow them to self-monitor their mood on a weekly basis and to return their results to their healthcare team by text or via a secure website. The team can then look at the results and advise on any treatment if required. We want to try using this system in people with diabetes who are about to start taking injections of insulin or GLP-1. We also want to know whether these two treatments have similar or different effects on people’s feelings.
The study will involve 20 individuals who are over the age of 18 years who have type 2 diabetes but whose blood glucose levels remain elevated (HbA1c ≥ 58 mmol/mol [≥ 7.5%]) despite being on the maximum doses of blood glucose lowering tablets and who have never previously used a self-injected medication. The individuals will attend one study visit in addition to their diabetes clinic appointments, complete two different questionnaires, one weekly and one monthly, throughout the 6-month duration of the study returning their responses in confidence to the research team.
REC name
West Midlands - Coventry & Warwickshire Research Ethics Committee
REC reference
13/WM/0220
Date of REC Opinion
2 Jul 2013
REC opinion
Further Information Favourable Opinion